Abstract Number: 1115 • 2019 ACR/ARP Annual Meeting
Switching Patterns Among Patients with Chronic Inflammatory Diseases Switching to an Infliximab Biosimilar or Remaining on Originator Infliximab (REMICADE)
Background/Purpose: Chronic inflammatory diseases (CIDs) such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), plaque psoriasis (PsO), ankylosing spondylitis (AS), Crohn's disease (CD), and ulcerative colitis…Abstract Number: 609 • 2018 ACR/ARHP Annual Meeting
Multi-Biologic Usage in Rheumatoid Arthritis Is Not Infrequent in the Routine Practice
Background/Purpose: Biologic DMARDs (bDMARDs) have proven efficacy in rheumatoid arthritis (RA) however, some patients inadequately response to multiple bDMARDs. This study aims to determine the…Abstract Number: 1490 • 2018 ACR/ARHP Annual Meeting
Effects of Biologic Drugs on Prognosis of Rheumatoid Arthritis Among Patients with Poor Glycated Hemoglobic A1c (HbA1c) Control
Background/Purpose: Poor control of glycated hemoglobic A1c (HbA1c) worsens prognosis for diabetes mellitus and various complicated diseases. Corticosteroids exacerbate poor HbA1c control. This study, investigated…Abstract Number: 2244 • 2016 ACR/ARHP Annual Meeting
Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
Background/Purpose: Adherence to medication is crucial to the maximum therapeutic benefit of biologic treatment. The plethora of currently approved biologic agents makes comparison…Abstract Number: 2249 • 2016 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Background/Purpose: While difficult to directly compare effectiveness of biologics in observational settings, drug discontinuation can be a useful substitute. We compared the discontinuation rates of…Abstract Number: 606 • 2016 ACR/ARHP Annual Meeting
A Randomized, Double Blind, Single Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of ONS-3010 (Adalimumab, Oncobiologics, Inc.) Compared to Two Reference Products of Humira® (AbbVie) in Healthy Adult Subjects
ONS-3010 is being developed as a biosimilar candidate of Humira® (Adalimumab), a full-length recombinant human IgG1 monoclonal antibody specific for TNFα. This study evaluated the b,…Abstract Number: 428 • 2015 ACR/ARHP Annual Meeting
Use of Rituximab Compared to Anti-TNF Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: 6-Year Follow-up Report from the Rhumadata® Clinical Database and Registry
Background/Purpose: The order of use of biologic agents after failing a TNF inhibitor is still a question for debate. Phase III trial data in TNF-IR…Abstract Number: 461 • 2015 ACR/ARHP Annual Meeting
Etanercept Has a Better Retention Rate at 10 Years Than Adalimumab in Patients with Rheumatoid Arthritis. Results from Rhumadata®: A Real-Life Clinical Database and Registry
Background/Purpose: Very few studies have compare different agents used in the treatment of rheumatoid arthritis (RA) over the very long term. The majority of them…Abstract Number: 480 • 2015 ACR/ARHP Annual Meeting
Comparative 10-Year Retention Rates of Adalimumab Used in Mono and Combination Therapy in Rheumatoid Arthritis (RA) Patients from the Rhumadata Clinical Database and Registry
Background/Purpose: The recent publication of the concerto trial comparing the use of adalimumab in monotherapy versus in association with methotrexate (MTX) at dose varying from…Abstract Number: 585 • 2015 ACR/ARHP Annual Meeting
Outcomes after Discontinuing Tumor Necrosis Factor Inhibitor in Rheumatoid Arthritis: 2 Years of ‘post-Golimumab’ after Completion of the 5-Year Extension Study in Korea
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) have helped patients achieve remarkable outcomes as in improving synovitis and halting structural damages in severe cases of rheumatoid…Abstract Number: 2514 • 2014 ACR/ARHP Annual Meeting
Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview
Background/Purpose During the last fifteen years, the role of biologics in the management of RA, the number of available biologics, and the recommendations of use,…Abstract Number: 2526 • 2014 ACR/ARHP Annual Meeting
Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components’ Evolution over Time
Background/Purpose The wide use of biological therapies (BTs) has clearly modified the therapeutic approach in rheumatoid arthritis (RA). One of the most commonly used tools…Abstract Number: 2383 • 2014 ACR/ARHP Annual Meeting
The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry
Background/Purpose Data on over-10-years drug survival of TNF inhibitors (TNFi) are still lacking. The aim of the study is to analysed the long-term retention rate…Abstract Number: 1149 • 2014 ACR/ARHP Annual Meeting
Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis
Background/Purpose: Adherence is under consideration for quality reporting in a number of disease states. Published data on adherence of biologics reveal a wide range of…Abstract Number: 2386 • 2013 ACR/ARHP Annual Meeting
Survival Of Biological Therapy In Rheumatoid Arthritis: 12 Years Follow-Up Cohort
Background/Purpose: After more than a decade of biological agents (BA) use for the treatment of rheumatoid arthritis (RA), it is necessary a thorough knowledge of…
ACR Meeting Abstracts